Application of QDSA Platform in Cerebrovascular Diseases
Launched by BEIJING TIANTAN HOSPITAL · Mar 24, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method called quantitative digital subtraction angiography (QDSA) to better understand cerebrovascular diseases, which are conditions affecting the blood vessels in the brain. These diseases can lead to serious health issues, including high rates of death and disability. The trial aims to see how effective QDSA is in helping doctors plan surgeries and make treatment decisions for patients with cerebrovascular diseases. By collecting and analyzing data from patients, the researchers hope to provide valuable insights that can improve care for these patients.
To be eligible for this study, participants need to have a diagnosed cerebrovascular disease assessed using a specific imaging technique called DSA, which must meet certain quality standards. People of all ages can participate, but they should be able to follow through with regular check-ups and treatment. If someone is dealing with other severe health issues or has participated in another trial recently, they may not be able to join. Participants can expect to have their condition monitored closely, and their data will help advance understanding and treatment of cerebrovascular diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Cerebrovascular diseases diagnosed and assessed by DSA for related risks and treatment options.
- • 2. The DSA acquisition protocol complies with the standard procedure.
- • 3. DSA images must include complete anteroposterior and lateral views.
- • 4. Raw data must be available in DICOM format.
- • 5. Image quality and pixel resolution must support data analysis.
- • 6. Patients must undergo regular follow-ups.
- Exclusion Criteria:
- • 1. Cerebrovascular diseases not diagnosed or risk-assessed using DSA.
- • 2. Patients with DSA image quality insufficient for image analysis and processing.
- • 3. Severe organ diseases with an expected survival period of less than 2 years.
- • 4. Inability to cooperate with treatment and follow-up.
- • 5. Participation in other clinical trials within the past 6 months.
- • 6. Other conditions deemed by the investigator as unsuitable for participation in this trial.
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported